お気に入りに追加
製品詳細
- ItemsSize 2mgSize 10mg (5mg × 2)Particle size2 μm2 μmPhysical appearancePowder mixturePowder mixtureBinding Capacity>137 pmol (20μg) Anti-VEGF antibody/mg beads>137 pmol (20 μg) Anti-VEGF antibody/mg beadsFormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% TrehaloseReconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
Product Description
The Human VEGF165-coupled Magnetic Beads is produced by coupling biotinylated human VEGF165 protein to streptavidin-conjugated magnetic beads. The pre-coupled beads are ready to use for capturing anti-VEGF165 antibody or VEGFR2/KDR protein from your sample with high specificity. The uniform size and large surface-to-volume ratio of the beads ensure highly efficent immunocapture in a simple, fast and convenient workflow with high reproducibilty of data.
Application
This product is intended for immunocapture, biopanning. This is a non-sterile product.
* The Isotype control (Cat. No. SMB-B01) is sold separately.
Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C.
Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
Assay Principles
Antibody Purification:
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACRO Quality Management System
お客様はこちらも閲覧
データ表示
Typical Data
Immobilized 31.6 μg VEGF165 protein/1mg beads can bind Anti-VEGF Antibody with an EC50 of 0.7726 μg/mL.
Protocol
Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the Human VEGF165-coupled Magnetic Beads (Cat.No. MBS-K036) and Bevacizumab showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.
Protocol
Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the Human VEGF165-coupled Magnetic Beads (Cat.No. MBS-K036) and Bevacizumab showed little deviation from the unfree-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.
Protocol
ユーザーレビュー コメントを投稿
よくある質問
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
最新の進展
医薬品開発の進捗- 英語名：
Vascular endothelial growth factor A
- カテゴリ：
- 市販の医薬品数：
54 詳細
- 治験医薬品数：
61 詳細
- 最新の開発ステージ：
Approved
お問い合わせ
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
医薬品候補ライセンス
